Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Marksans Pharma Limited
MARKSANSMarksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, upper respiratory, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. It also produces a range of solid oral dosage forms, including tablets and hard gelatin capsules; soft gels; essential oils; ointments; and creams and liquids, as well as prescription drugs. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India. Address: Grandeur, Mumbai, India, 400053
Analytics
Precio Objetivo de WallStreet
2 617.34 INRRelación P/E
40.8144Rentabilidad por dividendo
0.2 %Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave MARKSANS
Análisis de dividendos MARKSANS
Aumento del dividendo durante 5 años
900 %Crecimiento continuo
1 AñoRatio de pago medio en 5 años
5 %Tendencia del payout MARKSANS
Valoración de la acción MARKSANS
Finanzas MARKSANS
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |